Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5802 USD | -0.14% | -10.88% | -29.39% |
May. 30 | Brookline Capital Initiates Forte Biosciences at Buy Rating With $4 Price Target | MT |
May. 13 | Forte Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Turnover - Change in analysts' estimates
EBIT - Change in analysts' estimates
Turnover
EBIT
- Stock Market
- Equities
- FBRX Stock
- Revisions Forte Biosciences, Inc.